Uncategorized
International Study Shows Favorable 3-Year Results of 2 Glaukos iStent® Trabecular Micro-Bypass Stents as Initial Treatment for Naïve Glaucoma
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that an international study published in the current issue of Ophthalmology and Therapy showed that newly diagnosed primary open-angle glaucoma patients achieved a 43% reduction in mean intraocular pressure (IOP) to 14.6 mm Hg thro
